Genomic Instability Measured by Inter-(Simple Sequence Repeat) PCR and High-Resolution Microsatellite Instability are Prognostic of Colorectal Carcinoma Survival After Surgical Resection by Brenner, Bruce M. & Swede, Helen
University of Connecticut
OpenCommons@UConn
UCHC Articles - Research University of Connecticut Health Center Research
1-2012
Genomic Instability Measured by Inter-(Simple
Sequence Repeat) PCR and High-Resolution
Microsatellite Instability are Prognostic of
Colorectal Carcinoma Survival After Surgical
Resection
Bruce M. Brenner
University of Connecticut School of Medicine and Dentistry
Helen Swede
University of Connecticut School of Medicine and Dentistry
Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles
Part of the Medicine and Health Sciences Commons
Recommended Citation
Brenner, Bruce M. and Swede, Helen, "Genomic Instability Measured by Inter-(Simple Sequence Repeat) PCR and High-Resolution
Microsatellite Instability are Prognostic of Colorectal Carcinoma Survival After Surgical Resection" (2012). UCHC Articles - Research.
92.
https://opencommons.uconn.edu/uchcres_articles/92
Genomic Instability Measured by Inter-(Simple Sequence
Repeat) PCR and High-Resolution Microsatellite Instability are
Prognostic of Colorectal Carcinoma Survival After Surgical
Resection
Bruce M. Brenner, MD1, Helen Swede, PhD2, Beth A. Jones, PhD3, Garth R. Anderson,
PhD4, and Daniel L. Stoler, PhD5
1Division of Surgery, University of Connecticut Health Center, Farmington, CT
2Department of Community Medicine and Health Care and Neag Cancer Center, University of
Connecticut Health Center, Farmington, CT
3Department of Epidemiology and Public Health, Yale University, New Haven, CT
4Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY
5Department of Head and Neck Surgery, Roswell Park Cancer Institute, Buffalo, NY
Abstract
Background—During the multiyear progression to colorectal cancer, numerous genomic
alterations arise in events ranging from single base mutations to gains or losses of entire
chromosomes. A single genetic change might not stand out as an independent predictor of
outcome. The goal of this study was to determine if more comprehensive measurements of
genomic instability provide clinically relevant prognostic information.
Methods—Our study included 65 sporadic colorectal cancer patients diagnosed from 1987 to
1991 with last follow-up ascertained in 2006. We estimated an overall tally of alterations using the
genome-wide sampling technique of inter-(simple sequence repeat [SSR]) polymerase chain
reaction (PCR), and evaluated its relationship with all-cause survival. We also extended and
sensitized the Bethesda criteria for microsatellite instability (MSI), by analyzing 348 microsatellite
markers instead of the normal five. We expanded the MSI categories into four levels: MSI stable
(MSS), very low-level MSI, moderately low-level MSI, and classical high-level MSI.
Results—Tumors with genomic instability above the median value of 2.6% as measured by
inter-SSR PCR, were associated with far greater risk of death compared to tumors with lower
levels of genomic instability. Adverse outcome was most pronounced for patients presenting with
stage 3 disease. A gradient of increased survival was observed across increasing MSI levels but
did not reach statistical significance.
Conclusion—Our findings suggest genomic instabilities quantified by inter-SSR PCR and
increased precision in MSI values may be clinically useful tools for estimating prognosis in
colorectal cancer.
DNA sequencing has confirmed earlier cytogenetic, microarray and genomic sampling
approaches that had indicated carcinoma genomes are extensively damaged, with different
damage profiles evident in each tumor.1,2 Ten years ago, by genomic sampling, we
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estimated about 11,000 genomic events had occurred per colorectal tumor.3 With
approximately 1% of the genome representing coding sequences, these results are consistent
with more recent DNA sequencing studies finding around one hundred mutated genes per
tumor.4–6 This extensive overall alteration reflects the consequences of multiple genomic
instabilities arising at various times in tumor progression, combined with unrepaired
genomic damage resulting from environmental effects. One can anticipate that the nature
and extent of genomic instability in a tumor could impact clinical outcomes, by altering the
likelihood of deleterious genomic events occurring.
With high-level microsatellite instability (MSI-H), the tumor progression pathway is shifted
and tumors with MSI-H are associated with superior outcomes.7,8 Because microsatellite
instability (MSI) levels are generally determined by examination of only five markers, with
two or more altered being taken as MSI-H according to current National Cancer Institute
guidelines, lower level levels of MSI are difficult to precisely measure and possible outcome
differences within this group have not been evaluated.9 For larger event instabilities such as
copy number aberrations detected with microarray comparative genomic hybridization,
more extensively altered tumors have more gene functions altered or lost. Although there is
a greater likelihood of lethal events occurring in some members of the tumor cell population,
there is also a greater likelihood that some members of the tumor cell population have
evolved to more aggressive states. Studies of breast, colon, and prostate cancers have
confirmed that higher levels of large event instabilities are associated with generally worse
outcomes.10–12
Below we present the first report of the prognostic value of a tally of genomic instability as
estimated by inter-(simple sequence repeat [SSR]) polymerase chain reaction (PCR) in
colorectal tumors. We also evaluated the prognostic value of a more precise version of an
established measure of genomic instability, MSI, defined by genome-wide allelotyping with
348 microsatellite markers.
METHODS
Tumors and DNA Extraction
Paired colorectal tumor and normal mucosa samples were analyzed in these experiments.
The principal set of tissue samples were collected from 58 consecutive patients diagnosed
with sporadic colorectal cancer (CRC) who underwent surgery at Roswell Park Cancer
Institute, Buffalo, New York, between 1988 and 1995.13 These tissues were used for all of
the MSI determinations. An additional seven tissues were randomly selected from a Yale
study of patients diagnosed with primary CRC between January 1987 and April 1991.14
Both the Roswell Park and Yale specimens were used for the inter-SSR PCR
measurements.15 Patients gave their written consent to obtain tissue specimens, as approved
by the Roswell Park Cancer Institute institutional review board. Informed consent to obtain
tissues from patients was waived by the Yale Human Investigations Committee and all
participating hospital IRBs. Tissue samples were examined and tumor specific specimens
were selected by pathologists. DNA was extracted from liquid nitrogen-frozen tumor
samples and separately from adjacent normal tissue. Small pieces of the tissue
(approximately 8 mm 3) were digested with 1 mg/ml proteinase K for 3 h at 65°C, followed
by 0.5 mg/ml RNase treatment for 1 h. The DNA was then isolated via
phenol:choroform:isoamyl alcohol extraction and ethanol precipitation.
Genomic Instability Measurements
Inter-SSR PCR Instability—Inter-SSR instability was determined for all sixty-five paired
tumor and normal tissue DNAs as described.3,15 (CA)8RG and (CA)8RY (R = a 50:50
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mixture of the purines adenine and guanine; Y = a 50:50 mixture of the pyrimidines cytosine
and thymine) primers were end labeled with γ-32P-ATP via T4 polynucleotide kinase.
Amplification of sequences between the repeat elements was carried out in a 20 μl reaction
mixture containing 1 mM primer (1:5 labeled:unlabeled oligonucleotide), 50 ng genomic
DNA, 0.3 units Taq polymerase (Invitrogen Corporation, Carlsbad, CA) in 1× PCR buffer
(10 mM Tris-HCl, pH 9.0, 2% formamide, 50 mM KCl, 0.2 mM deoxynucleotide
triphosphates (dCTP, dATP, dTTP, dGTP), 1.5 mM MgCl2, 0.01% gelatin, 0.01% Triton
X-100). Amplification conditions were as follows: 2 min initial denaturation at 94°C,
followed by 35 cycles of 30 s at 94°C, 45 s at 52°C, 2 min at 72°C, and a final extension of
5 min at 72°C. PCR products were mixed with 10% loading buffer (40% sucrose, 0.25%
bromophenol blue) and 5 ml of each product was analyzed on a nondenaturing 8%
polyacrylamide gel without urea, buffered with 1× TBE (0.89 mM Tris-borate, pH 8.3, 2
mM EDTA). Electrophoresis was performed for 22 min at 80 W, followed by 50 W for 3400
volt-h. The gels were dried for 1 h and autoradiographed with Kodak XAR film with an
overnight exposure.
Low-Level MSI—Fractional allelic loss rate had been determined for the first 58
specimens by loss of heterozygosity electrophoretic gel analyses of PCR products, using 348
markers spaced an average 10 Mb apart, spanning the entire genome.13 The methodology
and loss of heterozygosity raw data has been reported previously.13 By evaluation of
banding patterns in the entire set of loss of heterozygosity gels for MSI at each of the 348
markers, precise MSI values were determined, including low-level MSI (MSI-L).
Statistical Analyses—Inter-SSR values were used to define two sets of patients
according to genomic instability index (GII). One group consisted of GII above (GII high)
and the second group GII below (GII low) the median level of 2.6% observed in the entire
sample.
The distribution of MSI levels were divided into four sets: zero markers exhibiting MSI
(MSI stable, or MSS), very low-level MSI (0.8–2.4% of informative markers), moderately
low-level MSI (2.5–9.6%), and high-level MSI (>40%). High-level MSI is based on the
Bethesda criteria.9 The MSI-low level was divided into two categories (above and below the
median of MSI-low values) for our analyses. Patient age at diagnosis, American Joint
Committee on Cancer stage at diagnosis, vital status, cause of death, sex, and race were
ascertained from the medical chart. Survival time was calculated from date of diagnosis to
date of last follow-up or of death. We last ascertained vital status in November 2006;
median follow-up time was calculated among patients still living at that point to determine
that adequate follow-up time had elapsed. Nonparametric tests were employed in descriptive
analyses as a result of the relatively small sample size in each study group. Survival analyses
employed the Cox proportional hazard test in multivariate analyses, and the method of
Kaplan-Meier to create survival curves. Before conducting survival studies, two patients
were excluded from analyses because they died less than 6 months after diagnosis to account
for possible bias related to surgical failure. Characteristics of these patients are as follows:
GII (1.3, 1.3), MSI (0.90, 3.14) stage (3, 4), survival in months (2.7 and 5.1), cause of death
(both non-CRC) and age (48, 47). All-cause survival was employed as the outcome measure
given the relatively small sample size. SPSS Ver. 18 was used in all analyses.
RESULTS
Inter-SSR PCR Instability Compared with Patient Outcomes
We first analyzed outcomes of patients previously assayed for genomic instability with
inter-SSR PCR at the time of tumor resection, and followed clinically for approximately the
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next decade.15 Instability by this method is quantified by the percentage of inter-SSR PCR
electrophoretic bands altered, defined as the GII. Clinicopathological characteristics
according to GII levels of tumors are reported in Table 1. Patients whose tumors exhibited
an increased GII level (GII high group) had a higher death rate from CRC compared to
patients in the GII low group (51.6 vs. 35.3%, respectively) and a higher overall mortality
rate (71.0 vs. 58.8%, respectively, data not shown) but these differences did not reach
statistical significance. Patients in the two GII groups did not vary substantially by age,
disease stage, sex, and race. Patients with GII high tumors tended to have reduced survival
time compared to those with GII low tumors (64.1 vs. 94.5 months, respectively, P = 0.20)
for all-cause mortality (Table 2). When examining CRC-specific death as the outcome of
interest, the difference in survival time was slightly more pronounced (63.7 vs. 104.4
months, respectively, P = 0.11, data not shown.) Stratified analyses show reduced median
survival time for patients with GII high tumors in each tumor, node, metastasis system
(TNM) stage.
Overall, patients with GII high tumors were more than twice as likely to die compared to
patients with GII low tumors (relative risk [RR] 2.42, 95% confidence interval [CI] 1.21–
4.85) after controlling for age, TNM stage and race (Table 2). For this analysis, we excluded
two patients who died shortly after surgery, whose deaths were not attributed to CRC. Cox
survival analyses stratified by TNM stage showed increased risk of death related to GII high
tumors at stages 1 to 3, although findings reached statistical significance for stage 3 disease
only (RR 4.35 95% CI 1.11–17.06). For patients with stage 1 disease, nearly all survived
after tumor resection, regardless of GII level. For patients with stage 4 disease, distant
metastases had already arisen before resection of the primary tumor, and the median survival
time of all these patients was low in both GII groups. Differences in outcomes based on GII
instability were most evident for stage 2 and 3 patients, presumably reflecting the likelihood
that occult metastasis had already occurred at the time of primary tumor resection.
Clinically, this information would be particularly useful for deciding which patients may
most benefit from adjuvant therapy.
Figure 1a illustrates the comparatively adverse survival rate of CRC patients with GII high
tumors (log rank test, P = 0.09) among those diagnosed with TNM stages 1, 2, and 3 (n =
52). The estimated 5- and 10-year survival rates for patients with GII high tumors was 65
and 35%, respectively, compared to 75 and 60%, respectively, for patients with GII low
tumors. Overall, the first loss to follow-up occurred after the 5 years. Figure 1b presents the
Kaplan-Meier survival curves among TNM stage 3 patients only (n = 20.) Notably, the 5-
year survival rate for patients with GII high tumors was 25% compared to 60% for GII low
tumors (log rank test, P = 0.037.) No stage 3 patients with GII high tumors survived past 6
years, whereas 35% of such patients with GII low tumors survived up to 10 years.
Low-Level MSI Compared with Patient Outcomes
MSI-L is defined by the Bethesda guidelines as the alteration of repeat sequences in one of
five specific microsatellite markers assayed.9 Because mismatch repair errors occur
randomly, this commonly used definition is open to considerable statistical error. Studies to
more precisely determine MSI-L have analyzed hundreds of microsatellite markers from
each tumor sample; such studies have revealed a broad distribution of low-level MSI values
ranging from zero to 10% of markers showing alterations, while classical high-level MSI
(MSI-H) shows more than 40% of markers altered.13,16
We investigated whether MSI-L cases of CRC have different outcomes, depending on the
degree of low-level instability. We followed up on the clinical outcomes of 58 cases we had
previously characterized at the genomic level in 2001, where 348 markers were examined
for MSI for each tumor specimen.13 The clinicopathologic features of these cases are
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described in Table 3. We divided these patients into four sets: those showing no
microsatellites altered (MSS, n = 6), those with below the median of MSI-L in the study
sample (MSI-L1, n = 25), those with above the median low-level MSI (MSI-L2, n = 23), and
those with high-level MSI (MSI-H, n = 4). The entire distribution of values is presented in
Fig. 2. Sex, race, or age did not vary by MSI status. The four MSI-H tumors were all stage 1
or 2, consistent with the well established superior outcomes for patients with MSI-H tumors.
The MSS, MSI-L1, and MSI-L2 tumors showed generally similar distributions among the
four stages.
The outcomes for the four different sets of patients exhibited a gradient of increased survival
as MSI level increased (Table 4), though this trend did not reach statistical significance.
MSI-H has long been associated with superior outcomes, as it was for our patients where the
median survival was 118.3 months. MSI-L2 patients showed a median survival of 92.7
months, while the value for MSI-L1 was 63.7 months. The MSS patients showed the worst
outcome, with a median survival of only 42.4 months.
Disease stage at diagnosis varied according to MSI status (P = 0.04.) Patients with MSI-high
tumors all presented with stage 1 or 2 disease at diagnosis, while 57% of patients with low
or no detectable levels of MSI in tumors were diagnosed at stage 3 or 4. MSI status did not
appear to vary by sex, race, or age. We did not perform multivariate analyses because of the
low number of MSS (n = 6) and MSI-high (n = 4) cases. Hence, we could not statistically
assess if MSI level was a favorable prognostic factor independent of stage at diagnosis.
DISCUSSION
For CRC patients after tumor resection, this is the first report of the prognostic value of
genomic instability as measured by inter-SSR PCR. We observed a statistically increased
risk of death associated with higher levels of inter-SSR PCR instability. In contrast, we
observed better outcomes associated with increasing levels of MSI by using a more precise
determination with 348 microsatellite markers. By themselves, these results are important;
perhaps if combined with genomic instability determinations made with microarray and
sequencing approaches or with spectral karyotyping, even more precise associations could
be found. Recent reports indicate another manifestation of genomic instability, DNA copy
number alteration, is also useful in estimating clinical outcome.10–12 By quantifying the
degree of genomic instability, we can get a sense of the likelihood that some cells within the
tumor cell population have progressed to a more lethal state. Because all tumors in our study
were surgically resected at the time of analysis, such a more lethal state likely relates to
undetected distant micrometastases left behind at the time of surgery. Future studies with
larger samples are warranted to confirm the prognostic value of genomic instability, and to
determine if this effect is maintained with the introduction of additional clinical data in
survival models such as treatment type and comorbidities.
MSI is a different case, where higher levels of MSI are associated with increasingly better
outcomes. Defects in DNA mismatch repair preferentially alter a small group of genes
containing DNA repeat sequences. This in turn causes tumor progression to follow a specific
pathway without large genomic events, which generates highly treatable tumors.17,18 Low-
level MSI may affect partial aspects of this same system, with higher degrees of low-level
instability approaching the superior outcomes observed with MSI-H. Alternatively, recent
identification of a microRNA system regulating DNA mismatch repair may relate to the
various low-level microsatellite instabilities observed, and a more complex association with
clinical outcome.19
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In tumor systems such as breast and prostate cancer, where early stage disease is frequently
observed but fewer tumors progress further, our approach of analyzing the extent and forms
of genomic instability might help provide a useful and practical means for differentiating
between those tumors that merit clinical intervention and those that do not.
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a Kaplan–Meier curves showing overall survival of GII high and GII low tumors among
patients diagnosed with TNM stage 1 to 3 CRC (n = 52).
b Kaplan–Meier curves showing overall survival of GII high and GII low tumors among
patients diagnosed with TNM stage 3 CRC (n = 20)
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Distribution of tumor MSI values and corresponding CRC patient survival times
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TABLE 1
Clinicopathological characteristics of 65 patients with CRC according to GII status of tumor
Characteristic GII lowan = 34 GII high n = 31 P b,c
Vital status
    Alive 14 (41.2%) 9 (29.0%) 0.41
    Dead from CRC 12 (35.3%) 16 (51.6%)
    Dead from other causes 8 (23.5%) 6 (19.4%)
Median follow-up (months)d 149.9 133.3 0.61
American Joint Committee on Cancer TNM stage at diagnosis
    1 10 (29.4%) 9 (29.0%) 0.83
    2 7 (20.6%) 6 (19.4%)
    3 9 (26.5%) 11 (35.5%)
    4 8 (23.5%) 5 (16.1%)
Colon subsitee
    Left 22 (66.7%) 19 (63.3%) 0.78
    Right 11 (33.3%) 11 (36.7%)
Age (years) (mean) 62.3 60.3 0.41
Sex
    Female 17 (50.0%) 16 (51.6%) 0.89
    Male 17 (50.0%) 15 (48.4%)
Race
    White 32 (94.1%) 27 (90.0%) 0.54
    Black 2 (5.9%) 3 (10.0%)
aGII as calculated from inter-SSR PCR assay. GII low and GII high categories are defined, respectively, as below and above median GII value for
entire sample of patients
b
Fisher's exact test for proportions (two-sided)
c
Mann-Whitney U nonparametric test for continuous values
dAmong patients alive at end of study period
e
Left colon defined as rectum through splenic flexure, right colon as transverse colon through cecum
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TABLE 2
Inter-SSR PCR instability: multivariate RR of death according to stage among 63 patients with CRC
Characteristic n Median survival (months) (SE) Risk of death
Adjusted RR 95% CIa
GII
    Low (0–2.6) 32 94.5 (10.3) 1.00 1.21–4.85
    High (>2.6) 31 64.1 (9.3) 2.42
Stage 1
    GII low 10 140.3 (15.1) 1.00 0.37–12.31
    GII high 9 106.3 (10.5) 2.14
Stage 2
    GII low 7 132.1 (24.6) 1.00 0.36–13.14
    GII high 6 127.4 (22.2) 2.17
Stage 3
    GII low 8 94.9 (17.2)b 1.00 1.11–17.06
    GII high 11 40.6 (5.2) 4.35
Stage 4
    GII low 7 23.0 (10.7) 1.00 0.21–1.44
    GII high 5 11.8 (10.7) 0.99
Excluded were two patients who died less than 6 months after diagnosis (see “Methods” section)
aCox proportional hazard survival analyses controlling for age, race, and TNM stage. Stage excluded from the multivariate model in stratified
analyses
b
Mann-Whitney U nonparametric test; P = 0.02 for stage 3 disease; all other tests, P > 0.20
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TABLE 3
Clinicopathological characteristics of 58 patients with CRC according to MSI status of tumor
MSI statusa,b MSS n = 6 MSI-L1 n = 25 MSI-L2 n = 23 MSI-H n = 4
Vital statusc
    Alive 0 8 (32.0%) 10 (43.5%) 2 (50.0%)
    Deaths from CRC 4 (66.7%) 11 (44.0%) 9 (39.1%) 1 (25.0%)
    Deaths from other causes 2 (33.3%) 6 (24.0%) 4 (17.4%) 1 (25.0%)
Median follow-up (months)d,e 0f 140.1 (14.3) 150.2 (9.4) 137.1 (76.7)
Disease stage at diagnosis
    1 0 7 (28.0%) 8 (34.8%) 1 (25.0%)
    2 1 (16.7%) 4 (16.0%) 3 (13.0%) 3 (75.0%)
    3 3 (50.0%) 8 (32.0%) 8 (34.8%) 0
    4 2 (33.3%) 6 (24.0%) 4 (17.4%) 0
Age (years) (mean)d 62.0 60.9 60.7 61.5
Sexc
    Female 4 (66.7%) 12 (48.0%) 9 (39.1%) 2 (50.0%)
    Male 2 (33.3%) 13 (52.0%) 14 (60.9%) 2 (50.0%)
Racec
    White 5 (83.3%) 24 (96.0%) 22 (100.0%) 3 (75.0%)
    Black 1 (16.7%) 1 (4.0%) 0 (0.0%) 1 (25.0%)
a
MSI as determined during genome-wide allelotyping assays.13 Cutpoints followed Bethesda criteria except for MSI-L1 and MSI-L2, which were
defined, respectively, as below and above the median within the category of MSI-L, as found in the Bethesda guidelines.9 MSS represents those
cases showing no MSI alterations among 348 microsatellites examined
bSeven had insufficient tissue for assay
c
Fisher's exact test for proportions (two-sided); all P > 0.10
d
Kruskal–Wallis test for continuous values; all P > 0.21
eAmong only patients alive at the end of the study period
fNo MSS patients alive at the end of the study period
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TABLE 4
Risk of death among 56 patients with CRC
MSI n Survival (months)a,b Multivariate-adjusted RR of deathb,c,d
Median All-cause 95% CI
MSS 6 42.4 (11.2) 1.00
MSI-L1 23 63.7 (11.5) 0.87 0.31–2.40
MSI-L2 23 92.7 (11.9) 0.71 0.24–2.09
MSI-H 4 118.3 (40.5) 0.46 0.05–4.70
MSS no microsatellite markers positive for instability, MSI-L1 <10% of markers positive, MSI-L2 ≥10 to <40% of markers positive, MSI-H ≥40%
of markers positive
a
Kruskal–Wallis nonparametric test = 3.93, P = 0.42
b
Excluded were 2 patients who died less than 6 months after diagnosis (see “Methods” section)
cCox proportional hazard survival analyses
dAdjusted for age, race, and TNM stage
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